Table 1.

Comparison between the excluded and the study samples characteristics (total N = 705)

		Excluded sample (n = 113)		Study sample (n = 592)		Test comparing study sample with excluded sample characteristics
		N	% or mean (sd)	N	% or mean (sd)
Treatment (total N = 696)	Intensive chemotherapy	7	7	187	32	p* < 0.001
	Best supporting care	81	12	179	30
	Hypomethylating agents	12	3	175	7
	Aracytine low dose	3	78	42	30
	Others	1	1	9	1
Patient’s characteristics
Age	Median (inter-quartile range)	80	10	74	12	p # < 0.001
Sex	Men	59	52	364	61	p § = 0.065
	Women	54	48	228	39
Patients’ SEP (EDI quintile) (total N = 613)	Q1 – least deprived	3	14	124	21
	Q2	6	29	104	18
	Q3	6	29	127	21	p * = 0.388
	Q4	5	24	137	23
	Q5 – most deprived	1	5	100	17
Charlson comorbidity index	0	20	19	261	44
	1	11	10	122	21	p § = 0.001
	2+	12	11	104	18
	Undefinable	64	60	105	18
Performance status	0/1	26	25	309	52
	2	13	13	91	15	p § = 0.001
	3/4	10	10	60	10
	Undefinable	55	53	132	22
Tumor’s characteristics
White blood cell counts (tercile) (total N = 599)	Tercile 1 – low	1	14	195	33
	Tercile 2 – intermediate	4	57	189	32	p * = 0.393
	Tercile 3 – high	2	29	193	33
	Undefinable	0	0	15	3
AML ontogeny (total N = 704)	AML de novo	36	32	301	51
	Secondary AML (post treatment / MDS)	41	37	268	45	p § < 0.001
	Undefinable	35	31	23	4
Cytogenetic initial prognosis	Favorable/Intermediate	50	44	343	58	p § < 0.001
	Unfavorable	26	23	203	34
	Undefinable	37	33	46	8

p-value for Fisher test *, chi-square test §, or Wilcoxon #